Target IRE1α signaling to reduce tumor proliferation and alter the tumor microenvironment; effective for both solid and liquid cancers. ORIN1001, a notable IRE1α-XBP1 blocker, is progressing in clinical trials. Here, XBP1 is linked to neoplasm.